HC Wainwright Has Negative Estimate for ORKA FY2024 Earnings

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Equities researchers at HC Wainwright cut their FY2024 earnings per share estimates for shares of Oruka Therapeutics in a research note issued to investors on Monday, November 25th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($2.24) per share for the year, down from their previous estimate of ($1.56). HC Wainwright has a “Buy” rating and a $45.00 price objective on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($3.10) per share. HC Wainwright also issued estimates for Oruka Therapeutics’ Q4 2024 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.52) EPS and FY2025 earnings at ($1.98) EPS.

A number of other analysts have also recently commented on the stock. Stifel Nicolaus initiated coverage on shares of Oruka Therapeutics in a research note on Friday, October 11th. They issued a “buy” rating and a $49.00 price target for the company. Leerink Partnrs raised shares of Oruka Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 17th. Jefferies Financial Group initiated coverage on Oruka Therapeutics in a research note on Friday, September 13th. They issued a “buy” rating and a $40.00 price target for the company. TD Cowen assumed coverage on shares of Oruka Therapeutics in a research report on Monday, September 16th. They set a “buy” rating on the stock. Finally, Lifesci Capital assumed coverage on Oruka Therapeutics in a research report on Monday, September 16th. They issued an “outperform” rating and a $41.00 price target on the stock. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Oruka Therapeutics currently has an average rating of “Buy” and an average price target of $43.17.

Oruka Therapeutics Trading Up 1.0 %

Oruka Therapeutics stock opened at $18.69 on Wednesday. The company has a fifty day simple moving average of $25.86. Oruka Therapeutics has a 1-year low of $18.20 and a 1-year high of $53.88. The company has a market capitalization of $654.15 million, a P/E ratio of -2.98 and a beta of 0.87.

Hedge Funds Weigh In On Oruka Therapeutics

A number of institutional investors have recently modified their holdings of the company. Geode Capital Management LLC bought a new stake in Oruka Therapeutics during the 3rd quarter valued at $343,000. The Manufacturers Life Insurance Company bought a new stake in shares of Oruka Therapeutics during the third quarter worth about $1,037,000. Wellington Management Group LLP bought a new stake in shares of Oruka Therapeutics during the third quarter worth about $2,013,000. Janus Henderson Group PLC acquired a new stake in shares of Oruka Therapeutics in the 3rd quarter worth about $5,840,000. Finally, Redmile Group LLC bought a new position in Oruka Therapeutics in the 3rd quarter valued at about $10,091,000. 56.44% of the stock is owned by institutional investors and hedge funds.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.